An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Liver International · 2026
DOI: 10.1111/liv.70586 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, 2026. Verfasst von Jiang-Shan Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Integrated Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichu…. Hauptthemen laut MEDLINE: Bile Acids and Salts, Signal Transduction, Fatty Liver, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 201 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, Luzhou Science and Technology Bureau.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a common metabolic disorder with rising global incidence without effective treatment. Emerging evidence highlights bile acids (BAs) as pivotal signalling molecules that modulate genes involved in their own metabolism and lipid homeostasis in hepatic and extrahepatic tissues, thereby influencing MASLD pathogenesis. These regulatory effects are primarily driven by the activation of nuclear receptors, including the farnesoid X receptor (FXR), vitamin D receptor (VDR), pregnane X receptor (PXR), and by the membrane‐bound G protein‐coupled receptors such as Takeda G protein‐coupled receptor 5 (TGR5) and sphingosine‐1‐phosphate receptor 2 (S1PR2). The distinct roles of these BA receptor‐dependent signalling pathways in lipid homeostasis underscore their importance in MASLD development. Pharmacological strategies targeting BA‐regulated pathways, particularly the FXR activation, have shown promise in MASLD treatment. Several FXR agonists, including obeticholic acid (OCA), cilofexor, and tropifexor, have progressed to clinical trials, demonstrating potential therapeutic efficacy. Additionally, recent studies identified several natural compounds—such as hyperoside, kaempferol, and salidroside—that exhibited direct or indirect FXR‐modulating properties, suggesting their potential utility for novel anti‐MASLD drug development. Further research into BA signalling mechanisms and the exploration of targeted therapies may provide novel and effective MASLD therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Integrated Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
- Research Center for Integrative Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
- Department of Endocrinology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, China.
- School of Biomedical Sciences, University of Queensland, St Lucia, Brisbane, Australia.
ORCID-Profile: Chen Chen, Hong-Lian Wang
Förderung
- Science and Technology Department of Sichuan Province
- Luzhou Science and Technology Bureau
Zitieren
APA
Shi, J. S., Wen, Y., Wang, L., Wu, L. J., Wang, L., Chen, C., Wang, H. L., & Zhao, C. Y. (2026). An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. https://doi.org/10.1111/liv.70586
Vancouver
Shi JS, Wen Y, Wang L, Wu LJ, Wang L, Chen C, et al. An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease. Liver International. 2026. doi:10.1111/liv.70586
BibTeX
@article{Shi2026,
author = {Shi, Jiang-Shan and Wen, Yi and Wang, Lu and Wu, Li-Juan and Wang, Li and Chen, Chen and Wang, Hong-Lian and Zhao, Chang-Ying},
title = {An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70586}
}
EUVIMED